Eli Lilly and Company is trading 5.2% up at $1135.25 following fresh enthusiasm around its obesity and diabetes franchise and evidence of strong institutional demand.
- Investor sentiment remains high as shares rebound from a brief pullback, with analysts noting euphoria surrounding the company's weight-loss drug portfolio.
- Renewed big-money buying is helping the stock outperform a mixed broader market as institutional investors increase positions.